Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : PoloMar Health LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Schizophrenia, Treatment-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 21, 2023
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : PoloMar Health LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Postoperative Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Amicus CD | Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Postoperative Nausea and Vomiting.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Amicus CD | Premier Research Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Details : With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.
Product Name : Barhemsys
Product Type : Miscellaneous
Upfront Cash : $78.5 million
June 09, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Charité Research Organisation | Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of a Single Dose of Amisulpride on Functional Brain Changes
Details : Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Charité Research Organisation | Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc
Details : Opportunity for Eagle’s highly skilled hospital-based salesforce to integrate and promote BYFAVO and BARHEMSYS and to leverage longstanding relationships to realize the full potential of these assets.
Product Name : Barhemsys
Product Type : Miscellaneous
Upfront Cash : $78.5 million
March 28, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Eagle Pharmaceuticals
Deal Size : $182.4 million
Deal Type : Acquisition
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sep-4199, enhance 5-HT7 receptor antagonist activity and reduce dopamine D2 receptor antagonist activity is in SEP380-301, Phase 3 clinical development for treatment of major depressive episodes associated with bipolar I disorder also showed positive Pha...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 09, 2022
Lead Product(s) : Amisulpride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Otsuka Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Barhemsys® is an intravenous formulation of amisulpride, a selective dopamine antagonist. It is approved in the US for treatment and prophylaxis of PONV, alone and in combination with other antiemetics.
Product Name : Barhemsys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
Details : Amisulpride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Amisulpride
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : $23.5 million
Deal Type : Financing
Details : The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference...
Product Name : Barhemsys
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 18, 2021
Lead Product(s) : Amisulpride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : $23.5 million
Deal Type : Financing